文献速递腹部介入CTMR

肝细胞癌射频消融后介入前MR成像与肝脏灌注CT融合:局部复发的早期定量预测

Fusion of Preinterventional MR Imaging With Liver Perfusion CT After RFA of Hepatocellular Carcinoma: Early Quantitative Prediction of Local Recurrence.
PubMed 文献 · Invest Radiol · 2021-01-01

本研究纳入39例患者共43个肝细胞癌,将射频消融前MR图像非刚性配准至消融后24小时内灌注CT,定量分析消融区与肿瘤的灌注参数差值。局部复发组肿瘤较大而消融区较小,灌注参数差值可准确区分复发,尤其归一化峰值强化和动脉肝灌注差值以零为阈值时全部病例判断正确。

要点

  • 消融后24小时内灌注CT与术前MR融合可行,配准成功率94.9%。
  • 局部复发组肿瘤较大(22.7±3.9 cm vs 17.8±5.3 cm,P=0.035),消融区较小(29.8±6.9 cm vs 39.3±6.8 cm,P=0.014)。
  • 归一化峰值强化和动脉肝灌注的差值(消融区减肿瘤)以零为阈值可准确区分局部复发与无复发。

核心结论

  • 将射频消融前MR图像配准至消融后灌注CT可行,能在消融后24小时内以客观定量方式预测局部肿瘤复发,准确率优良。

研究设计与样本

  • 经机构审查委员会批准的研究,纳入39例患者(78.4%男性,平均年龄68.2±8.5岁)共43个肝细胞癌,均在本机构接受射频消融并有诊断性消融前MR和消融后灌注CT。
  • 消融后灌注CT在射频消融后24小时内完成。
  • 先将显示肝细胞癌的消融前MR图像非刚性配准至消融后灌注CT,再将MR数据与计算出的灌注参数容积共同载入灌注应用进行定量分析。
  • 围绕肝细胞癌和消融区绘制三维感兴趣容积,两个轮廓自动投影至所有灌注图,记录灌注值(归一化峰值强化[%]、动脉肝灌注[mL/min/100 mL]、血流量[mL/100 mL/min]、血容量[mL/100 mL])及直方图数据。
  • 局部肿瘤复发根据EASL指南在随访影像上定义。

关键影像表现/征象

  • MR与CT图像配准在37例患者中成功(94.9%)。
  • 局部肿瘤复发见于5个肝细胞癌(12%)。
  • 局部复发组肿瘤大小22.7±3.9 cm,无局部复发组17.8±5.3 cm,局部复发组显著较大(P=0.035)。
  • 局部复发组消融区大小29.8±6.9 cm,无局部复发组39.3±6.8 cm,局部复发组显著较小(P=0.014)。
  • 灌注参数归一化峰值强化、动脉肝灌注、血流量和血容量的差值(消融区减肿瘤)在两组间均显著不同(所有P<0.005)。

诊断标准与关键数值

  • 归一化峰值强化和动脉肝灌注的差值(消融区减肿瘤)以零为阈值,在所有病例中准确区分局部肿瘤复发与无局部复发。
  • 这些灌注参数的差值为负时,在所有病例中识别出局部肿瘤复发。

临床应用与阅片要点

  • 消融后24小时内灌注CT与术前MR融合可定量评估消融区与肿瘤的灌注差异,辅助早期预测局部复发。
  • 归一化峰值强化和动脉肝灌注的差值(消融区减肿瘤)为负值时提示局部肿瘤复发可能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The aim of this study was to evaluate the ability of fusion of pretreatment magnetic resonance (MR) imaging with posttreatment perfusion-CT (P-CT) after radiofrequency ablation (RFA) of hepatocellular carcinomas (HCCs) and to determine treatment success in an objective, quantitative way.

MATERIALS AND METHODS: In this institutional review board-approved study, 39 patients (78.4% male; mean age 68.2 ± 8.5 years) with a total of 43 HCCs, who underwent RFA at our institution and had diagnostic pre-RFA MR imaging and post-RFA P-CT, were included in the study. Post-RFA P-CT was performed within 24 hours after RFA. In a first step, the pre-RFA MR imaging, depicting the HCC, was registered onto the post-RFA P-CT using nonrigid image registration. After image registration, the MR data were reloaded jointly with the calculated perfusion parameter volumes into the perfusion application for quantitative analysis. A 3-dimensional volume of interest was drawn around the HCC and the ablation zone; both outlines were automatically projected onto all perfusion maps. Resulting perfusion values (normalized peak enhancement [NPE, %]; arterial liver perfusion [ALP, in mL/min/100 mL]; BF [blood flow, mL/100 mL/min]; and blood volume [BV, mL/100 mL]) and histogram data were recorded. Local tumor recurrence was defined in follow-up imaging according to the EASL guidelines.

RESULTS: Image registration of MR imaging and CT data was successful in 37 patients (94.9%). Local tumor recurrence was observed in 5 HCCs (12%). In the local tumor recurrence group (LTR-group), HCC size was significantly larger (22.7 ± 3.9 cm vs 17.8 ± 5.3 cm, P = 0.035) and the ablation zone was significantly smaller (29.8 ± 6.9 cm vs 39.3 ± 6.8 cm, P = 0.014) compared with the no-local tumor recurrence group (no-LTR group). The differences (ablation zone - tumor) of the perfusion parameters NPE, ALP, BF, and BV significantly differed between the 2 groups (all P's < 0.005). Especially, the difference (ablation zone - tumor) of NPE and ALP, with a cutoff value of zero, accurately differentiated between LTR or no-LTR in all cases. A negative difference of these perfusion parameters identified local tumor recurrence in all cases.

CONCLUSIONS: Image registration of pre-RFA MR imaging onto post-RFA P-CT is feasible and allows to predict local tumor recurrence within 24 hours after RFA in an objective, quantitative manner and with excellent accuracy.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Kobe A, Kindler Y, Klotz E, et al. Fusion of Preinterventional MR Imaging With Liver Perfusion CT After RFA of Hepatocellular Carcinoma: Early Quantitative Prediction of Local Recurrence. Invest Radiol. 2021. PMID: 32932379. doi:10.1097/RLI.0000000000000726

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。